CRL — Charles River Laboratories International, Inc.

The Q2 2026 earnings reaction was sharply positive: revenue beat by roughly $25M, non-GAAP EPS came in at $3.02 versus $2.73 expected, DSA book-to-bill reached about 1.2x (highest in nearly four years), and management raised FY2026 revenue, EPS, and free cash flow guidance. Analysts responded with target increases into the $282-$300 range. That said, bullishness is now visible in the tape: as of 2026-08-27, price is +50.8% above its 200-day SMA and RSI is 73.88, so the recovery is already partly priced in.

Revenue has essentially flat-lined around $1.0B per quarter for three years; Q2 2026 was down 2.7% year-over-year after roughly -0.5% to +1% in prior quarters, so there is no organic growth yet. GAAP net income is polluted by large impairments in Q4 2024 (-$215.7M) and Q4 2025 (-$276.6M), but operating income troughed at $74.7M (7.6% margin) in Q1 2025 and has stabilized around $120M per quarter (~12% margin) for the last three quarters. Gross margin jumped to 36.2% in Q2 2026 from about 28% in Q1 2026, and Q2 free cash flow was $148.6M versus -$14.8M in Q1 2026. This is a cyclical stabilization/inflection, not yet a steady-growth story.

As of 2026-08-27, the trailing GAAP P/E of -61.2x is meaningless because impairment-driven losses distort EPS. On forward numbers, at $296.41 the stock trades about 26.2x FY2026 non-GAAP EPS of $11.32 and about 23.7x FY2027 EPS of $12.49. Price-to-sales of 3.57x is about 12% above CRL's own 5-year average of 3.19x. Despite the deterministic label 'Cheap vs. its own history,' the stock is not cheap on forward earnings; it is roughly full, with the analyst consensus price target of $267.6 sitting below the current price.

The price has moved well ahead of reported earnings and is pricing in a successful cyclical recovery before revenue has turned positive. If DSA book-to-bill stays above 1.0x and FY2027 EPS of about $12.49 materializes, $296 is defensible at roughly 24x forward earnings. If the biotech funding thaw stalls, downside is toward the $263-$280 analyst range. The stock is no longer underpricing the turnaround; it is paying up for it.

As of 2026-08-27, RSI-14 is 73.88, price is +7.28% above the 20-day SMA, +22.02% above the 50-day SMA, and +50.81% above the 200-day SMA. That is a powerful uptrend but also an overbought and extended one. Entry timing is poor until RSI cools or price pulls back toward the 20- or 50-day moving averages.

• Biotech funding thaw: improving VC and secondary equity issuance is refilling preclinical pipelines after a multi-quarter drought.
• Interest rates: gradual cuts have stabilized clients' cost of capital, the key driver for early-stage outsourced R&D demand.
• NHP supply and regulation: secure non-human primate sourcing is a structural moat but also a regulatory and geopolitical concentration risk.
• Pharma AI/ML partnerships: collaborations like Lilly's TuneLab could expand the market for nonclinical safety data.
• Outsourcing trend: cost pressure at large pharma continues to favor external CRO partners over in-house capacity.

• Q3 2026 earnings (late October/early November 2026): need to see DSA book-to-bill hold above 1.0x and revenue growth turn positive.
• FY2026 guidance follow-through: non-GAAP EPS of $11.15-$11.45 and FCF of $400M-$420M; upside if biotech funding accelerates.
• Expanded NGS and AI/ML data partnerships (Medigen, Arovella, Lilly TuneLab) and potential new framework deals.

• Recovery reversal: if biotech funding or order flow re-freezes, book-to-bill and revenue guidance will disappoint.
• Leverage: long-term debt of $2.62B and debt-to-equity of 1.07x leave limited balance-sheet flexibility if rates rise or EBITDA contracts.
• Impairment/GAAP loss risk: the company has taken large charges in two of the last six quarters; further write-downs would pressure book value and sentiment.
• Valuation/mean-reversion: with RSI at 73.88 and price above the consensus target, a pullback is the more likely near-term scenario.

The underlying business is turning: order book, guidance, and free cash flow all improved in Q2 2026. But at $296.41 as of 2026-08-27, that recovery is largely reflected in the price—roughly 26x this year's non-GAAP EPS, above the average analyst target, and technically overbought. I would not chase here; a pullback toward the $260s or evidence of positive revenue growth would make the risk/reward meaningfully better.

I blended 24.0x FY2026 non-GAAP EPS of $11.32 ($272) with 23.0x FY2027 EPS of $12.49 ($287), weighting them roughly equally to get about $279. The multiple is below historical euphoric levels because revenue growth is still near zero and debt-to-equity is above 1.0x, but above the current GAAP multiple because impairment-weighted trailing earnings understate normalized profitability.